Prominent immunotherapy specialists form new board; will provide strategic guidance for application of next-generation DiversitAb™ Platform
January 21, 2016 09:32 AM Eastern Standard Time
SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, focused on advancing some of the most innovative molecular genetics and human antibody technology in the world, today announced the appointment of four internationally respected immunotherapy specialists to its newly formed Scientific Advisory Board.
These globally recognized scientists and physicians will serve as a strategic resource to SAB as it develops therapeutic applications for its antibody production technology. SAB’s DiversitAb™ Platform is a next-generation technology for the production of fully human, precision-targeted antibody therapeutics to treat a diverse range of diseases. The proprietary DiversitAb technology is well advanced, having proven effective on multiple targets in numerous scientific validations. The platform is poised to produce antibody products for specific targeted applications.
“We are honored to welcome these respected experts to join us in SAB’s mission to deliver diverse and highly effective antibody solutions,” said Dr. Eddie Sullivan, President and CEO. “We are in the process of commercializing our next-generation technology and ultimately delivering the most relevant and impactful therapeutics. We look forward to the skills, insights and wisdom of this new board in advancing these initiatives.“
The Board is comprised of a team of distinguished immunotherapy leaders with diverse perspectives to provide valuable scientific and clinical insights, in infectious disease, oncology, viral infections and autoimmune disorders, as the Company advances antibody products through clinical trials.
The members of SAB Biotherapeutics’ new Scientific Advisory Board include:
- James Robl, Ph.D.,Scientist and Biotech Entrepreneur
James Robl, Ph.D. is an internationally recognized scientist and entrepreneur specialized in transgenic animals and cloning in cattle. He is a former professor at the University of Massachusetts-Amherst and founder of the project that led to the underlying technologies of the DiversitAb Platform antibody production technology and Tc Bovine™. Dr. Robl will serve as the Chairman of the advisory board. - Arturo Casadevall, M.D., Ph.D.,Johns Hopkins Bloomberg School of Public Health
Dr. Casadevall is an internationally recognized expert in infectious disease research, with a focus on fungal and bacterial pathogenesis and basic immunology of antibody structure-function.He is a Bloomberg Distinguished Professor of Molecular Microbiology & Immunology and Infectious Diseases at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, and the Alfred and Jill Sommer Professor and Chair of the W. Harry Feinstone Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health. - Michael Haller, M.D., MS-CI,University of Florida Medical Center
Dr. Haller is Associate Professor of Pediatrics at the University of Florida Medical Center and an active investigator in the NIH funded Type 1 diabetes TrialNet and The Environmental Determinants of Diabetes in Youth (TEDDY) study. He is the PI of promising studies seeking to utilize combination therapies with antithymocyte globulin (ATG) and granulocyte colony stimulating factor (GCSF) in patients with both recent onset and established Type 1 diabetes. In addition, Dr. Haller served as the PI of a “first in man” study aimed at using autologous umbilical cord blood stem cells as a potential therapy for Type 1 diabetes. - Frederick Hayden, M.D., University of Virginia School of Medicine
Dr. Hayden is Richardson Professor of Clinical Virology in the Department of Medicine at the University of Virginia School of Medicine. He is internationally recognized for his work with the application of antiviral agents for the prevention and treatment of respiratory viral infections, including influenza and rhinovirus infections and other respiratory viral diseases. Dr. Hayden has published over 300 peer-reviewed articles, chapters and reviews and co-edited the textbook Clinical Virology. He works with the WHO-Global Influenza Programme and as an advisor to the International Several Acute Respiratory and Emerging Infection Consortium (ISARIC) as well as serving as the Influenza Research Coordinator at Wellcome Trust and as a consultant to the NIAID supported Southeast Asia Infectious Diseases Clinical Research Network.
“SAB has a novel technology with the DiversitAb Platform that promises important new therapeutic opportunities across a range of clinical indications where significant unmet medical needs exist,” said newly appointed Board member, Dr. Arturo Casadevall. “I look forward to working with the SAB team and these distinguished colleagues to pursue these initiatives and bring new antibody products to patients and health care providers around the world.”
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, South Dakota is an established, biopharmaceutical company that is leading the science and manufacturing of polyclonal antibody therapies. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large scale platform to create fully human, polyclonal antibodies. This natural production platform holds the promise of treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
For more information visit: www.sabbiotherapuetics.com.
Contacts
SAB Biotherapeutics, Inc.Melissa Ullerich, 605-685-8350
media@sab.bio
